Company intelligence / Profile preview

D-Pharm

Ownership: Private
Development stage: Other

Overview

D‑Pharm develops innovative small-molecule drugs targeting devastating brain disorders using proprietary lipid-based technology platforms. Its lead candidates—DP-b99 for stroke and DP-VPA for epilepsy—are both in Phase II clinical development. Additional applications include traumatic brain injury, CABG-associated risk reduction, bipolar disorder, migraine prophylaxis, and a preclinical Alzheimer’s program. The company also has a broader early-stage pipeline addressing neurodegenerative diseases, CNS disorders, and cancer.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeLipid-like small molecule (proprietary platform)
Industry: Biotech

Drug pipeline

3 assets

DP-b99

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on D-Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-Pharm.

Explore the full profile